Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin and Lansoprazole for Prevention of Preterm Birth
NCT07337655Phase 3Not yet recruiting
- Sponsor
- Stanford University
- Start
- Oct 2026
- Primary completion
- Sep 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in preterm birth comparing Combination Therapy (Aspirin & Lansoprazole) with Standard of Care (2 arms). Primary endpoint: Incidence of Preterm Birth before 37+0 weeks of gestation. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
aspirinlansoprazole
03
Conditions
preterm birth
Beyond the preview
Go deeper on NCT07337655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337655.